Timothy A Springer bought $965k of RNAC
director, owner at Cartesian Therapeutics, Inc.. 52,189 shares at an average of $18.49, traded Dec 19, 2024, filed Dec 23, 2024.
Score components
- +15RoleDirector
- +25Trade size$965k at market
- -5Relative to holdingsUnder 1% of holdings (0.6%)
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001453687-24-000147, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2024 | POpen-market purchase Common Stock | +11,303 | $17.39 | $197k | 8,467,009 | Dec 23, 2024 |
| Dec 19, 2024 | POpen-market purchase Common Stock | +10,529 | $18.35 | $193k | 8,477,538 | Dec 23, 2024 |
| Dec 19, 2024 | POpen-market purchase Common Stock | +3,376 | $18.93 | $64k | 8,480,914 | Dec 23, 2024 |
| Dec 20, 2024 | POpen-market purchase Common Stock | +21,800 | $18.94 | $413k | 8,502,714 | Dec 23, 2024 |
| Dec 23, 2024 | POpen-market purchase Common Stock | +5,181 | $19.00 | $98k | 8,507,895 | Dec 23, 2024 |
Related signals
Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.5M 149,075 shares | +2% | |
| 45Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.4M 89,863 shares | +1% | |
| 30Weak | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $366k 20,967 shares | +0% | |
| 54Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $290k 17,271 shares | -8% | |
| 48Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $134k 7,989 shares | -8% | |
| 40Moderate | Cartesian Therapeutics, Inc. | Emily English Chief Operations Officer | $30k 1,797 shares | -4% | |
| 36Weak | Cartesian Therapeutics, Inc. | Christopher M Jewell Chief Scientific Officer | $43k 2,550 shares | -5% | |
| 35Weak | Cartesian Therapeutics, Inc. | Milos Miljkovic Chief Medical Officer | $32k 1,880 shares | -5% | |
| 39Weak | Cartesian Therapeutics, Inc. | Metin Kurtoglu Chief Technology Officer | $82k 4,875 shares | -7% | |
| 20Weak | RNACsell Cartesian Therapeutics, Inc. | Metin Kurtoglu Chief Technology Officer | $345k 13,664 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.